Premium
Fetal serum α ‐1 microglobulin for renal function assessment: comparison with β 2‐microglobulin and cystatin C
Author(s) -
Nguyen Claire,
Dreux Sophie,
Heidet Laurence,
Czerkiewicz Isabelle,
Salomon Laurent J.,
Guimiot Fabien,
Schmitz Thomas,
Tsatsaris Vassilis,
Boulot Pierre,
Rousseau Thierry,
Muller Françoise
Publication year - 2013
Publication title -
prenatal diagnosis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.956
H-Index - 97
eISSN - 1097-0223
pISSN - 0197-3851
DOI - 10.1002/pd.4128
Subject(s) - beta 2 microglobulin , renal function , medicine , cystatin c , kidney , creatinine , urinary system , cystatin , fetus , endocrinology , urology , biology , pregnancy , genetics
Objective To compare the prognostic value of fetal serum α 1‐microglobulin with that of β 2‐microglobulin and cystatin C for postnatal renal function. Method Retrospective study of α 1‐microglobulin, β 2‐microglobulin, and cystatin C in fetal serum from 126 fetuses with congenital abnormalities of the kidney and urinary tract (73 and 53, respectively). Two groups were defined: group with normal renal function and group with renal failure. For live born infants, renal function was assessed on the basis of serum creatinine (cutoff 50 µmol/L) or glomerular filtration rate (cutoff 75 mL/min/1.73 m2) or both. In case of infant or fetal death, histological kidney lesions were considered. Results Significant differences ( p < 0.001) were observed for the three markers between fetuses with good renal prognosis and those with renal failure (34.4 mg/L vs 67.6 mg/L for α 1‐microglobulin, respectively; 3.9 mg/L vs 7.35 mg/L, for β 2‐microglobulin, respectively; and 1.67 mg/L vs 2.12 mg/L for cystatin C, respectively). Areas under receiver operator curves were used to compare the three markers, 0.96, 0.90, and 0.74 for β 2‐microglobulin, α 1‐microglobulin, and cystatin C, respectively. Conclusion Although α 1‐microglobulin is significantly different in fetuses with good renal prognosis and those with renal failure, overall, it is a less reliable prognostic marker than fetal serum β 2‐microglobulin. © 2013 John Wiley & Sons, Ltd.